You are here

Scheduling delegate's final decisions, October 2017

Scheduling medicines and poisons

31 October 2017

Book pagination

2. Summary of delegate’s final decisions

Part A - Final decisions on matters referred to an expert advisory committee

Advisory Committee on Medicines Scheduling (ACMS #21)

Summary of delegate's final decisions
Substance Final decision
Sildenafil The current scheduling of sildenafil remains appropriate.
Vardenafil The current scheduling of vardenafil remains appropriate
Ibuprofen combined with paracetamol The current scheduling of ibuprofen combined with paracetamol remains appropriate.

Schedule 4 – Amend Entry

ESOMEPRAZOLE except when included in Schedule 2.

Schedule 3 – Delete Entry

Schedule 2 – Amend Entry

ESOMEPRAZOLE in oral preparations containing 20 mg or less per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.


Appendix K – New Entry


Book pagination